Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868248 | 0.84 | CNR2 (0.40) | ALOX5FAAHALDH1A1TDP1MEN1 | |
| SCHEMBL14868581 | 0.82 | ALDH1A1 (0.39) | ALOX5TSHRFAAHALDH1A1TDP1 | |
| SCHEMBL14868662 | 0.80 | FAAH (0.36) | ALOX5TSHRFAAHALDH1A1TDP1 | |
| SCHEMBL14868657 | 0.80 | ALDH1A1 (0.37) | ALOX5TSHRFAAHALDH1A1TDP1 | |
| SCHEMBL1520136 | 0.75 | GRIN2D (0.49) | TSHRALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL23135429 | 0.74 | EPHX2 (0.41) | TSHRALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL4465134 | 0.74 | GRIN2D (0.47) | TSHRALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14868571 | 0.73 | ALOX5 (0.40) | ALOX5TSHRFAAHALDH1A1TDP1 | |
| SCHEMBL17777347 | 0.72 | PLA2G1B (0.52) | TSHRALDH1A1KMT2AHPGDHTT | |
| SCHEMBL1040794 | 0.72 | CYP2C9 (0.58) | ALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-2800561-B1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMA US LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-7396858-B2 | Biguanide derivative and therapeutic agent for diabetes containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396858-B2 | Biguanide derivative and therapeutic agent for diabetes containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396858-B2 | Biguanide derivative and therapeutic agent for diabetes containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1500656-B1 | BIGUANIDE DERIVATIVES AND THEIR USE AS ANTIDIABETIC DRUGS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1500656-B1 | BIGUANIDE DERIVATIVES AND THEIR USE AS ANTIDIABETIC DRUGS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20050124693-A1 | Biguanide derivative and therapeutic agent for diabetes containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1500656-A1 | BIGUANIDE DERIVATIVE AND THERAPEUTIC AGENT FOR DIABETES CONTAINING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124693-A1 | Biguanide derivative and therapeutic agent for diabetes containing the same | SLC5A1, SLC5A2, GLP1R | ALOX5 3114/4885TSHR 672/4885FAAH 3823/4885 |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALOX5 2462/4885TSHR 2290/4885FAAH 3375/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALOX5 2462/4885TSHR 2290/4885FAAH 3375/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALOX5 2462/4885TSHR 2290/4885FAAH 3375/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALOX5 2462/4885TSHR 2290/4885FAAH 3375/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | ALOX5 2462/4885TSHR 2290/4885FAAH 3375/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ALOX5 2462/4885TSHR 2290/4885FAAH 3375/4885 |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ALOX5 2462/4885TSHR 2290/4885FAAH 3375/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | ALOX5 2642/4885TSHR 2314/4885FAAH 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.